Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma

Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus and Carolyn J. Anderson
Journal of Nuclear Medicine December 2018, 59 (12) 1843-1849; DOI: https://doi.org/10.2967/jnumed.118.209510
Jaeyeon Choi
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wissam Beaino
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
3VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald J. Fecek
4Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kellsye P.L. Fabian
5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles M. Laymon
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda F. Kurland
6Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter J. Storkus
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
4Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn J. Anderson
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
7Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; and
8Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (12)
Journal of Nuclear Medicine
Vol. 59, Issue 12
December 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus, Carolyn J. Anderson
Journal of Nuclear Medicine Dec 2018, 59 (12) 1843-1849; DOI: 10.2967/jnumed.118.209510

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus, Carolyn J. Anderson
Journal of Nuclear Medicine Dec 2018, 59 (12) 1843-1849; DOI: 10.2967/jnumed.118.209510
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
  • Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
  • Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
  • CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer
  • Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
  • Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury
  • Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
  • Cell Adhesion Molecules in Plasticity and Metastasis
  • Combination Strategies to Improve Targeted Radionuclide Therapy
  • Google Scholar

More in this TOC Section

Oncology

  • Comparative PSMA expression at early (1hour) vs late (2hour) in primary and secondary sites of involvement in prostate cancer.
  • Imaging spectrum of peritoneal carcinomatosis associated with various etiologies on 18F-FDG PET/CT
  • Hybrid Imaging Features of Musculoskeletal Tumors
Show more Oncology

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • melanoma
  • immune checkpoint inhibitors
  • targeted radionuclide therapy
  • VLA-4
  • PET imaging
SNMMI

© 2025 SNMMI

Powered by HighWire